Navigation Links
Signal may send cancer's cellular factories into overdrive
Date:7/9/2014

A network of signals active in almost all types of cancer sends the protein factories in our cells into overdrive, and may help fuel a tumour's uncontrolled growth, new research suggests.

Scientists at The Institute of Cancer Research, London, identified a molecular trigger responsible for ratcheting up activity of the endoplasmic reticulum (ER) the cellular factory that makes the building blocks cancer cells need to keep growing.

A protein in the TOR signalling pathway, called SREBP, controls the flow of messages to the endoplasmic reticulum telling it to expand and could allow cancer cells to produce enough proteins and lipids to fuel their non-stop growth.

The findings may help to explain how cancer cells maintain their high levels of metabolism and could uncover future targets for cancer treatment.

The study was published in the journal PLOS ONE, and funded by the Biotechnology and Biological Sciences Research Council (BBSRC), with additional support from the Wellcome Trust.

Unlike healthy cells, cancer cells are constantly growing, and so need to keep making proteins and lipids - the building blocks of all cells.

In healthy cells constant growth can overwhelm cellular factories like the ER, leading to cell stress and death, but cancer cells manage to keep their factories running at high capacity to fuel non-stop growth.

Scientists at The Institute of Cancer Research (ICR) used the cells of fruit flies, modified with a fluorescent marker that is activated when the cells are put under stress, to identify the signals responsible for driving up activity of the ER.

They systematically silenced genes thought to be important to the smooth working of the ER and measured the stress signals produced in response.

They found that silencing the TOR signalling pathway - activated in many different types of cancer - increased ER stress in the cells. When they blocked TOR signals, cells took longer to recover from ER stress and the ER factory shrank.

Their findings suggest the TOR signalling pathway promotes cell growth while simultaneously ensuring productivity of the ER matches this growth. And the protein SREBP, which is part of the TOR signalling pathway, appeared to be essential for promoting expansion of the ER, and ensuring it carried out its factory activities effectively.

Lead author Dr Chris Bakal, leader of the Dynamical Cell Systems Team at The Institute of Cancer Research, London, said: "The endoplasmic reticulum is the factory of our cells, creating the proteins and lipids needed for our cells to grow and proliferate. In cancer cells, this factory is active all the time, churning out the building blocks that cancer cells need for their rapid growth.

"We have discovered the key role played by the TOR signalling pathway in driving the expansion of the endoplasmic reticulum, and sending a cell's factories into overdrive. The TOR pathway is active in many types of cancer, and our study provides new insights into how cancer metabolism works, and suggests that these metabolic signals could be excellent targets for future treatments."


'/>"/>
Contact: Graham Shaw
graham.shaw@icr.ac.uk
020-715-35380
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Related medicine news :

1. Signaling pathway may explain the body clocks link to mental illness
2. MAD: Scientists shed light on braking mechanisms in cellular signaling
3. Brain signals link physical fitness to better language skills in kids
4. Signals found that recruit host animals cells, enabling breast cancer metastasis
5. Nightmares may signal a child is being bullied
6. DNA modifications measured in blood signal related changes in the brain
7. Molecular aberration signals cancer
8. Tinnitus study signals advance in understanding link between loud sounds exposure and hearing loss
9. Long distance signals protect brain from viral infections
10. Prostate cancer signal reawakens sleeper agent cells in bones
11. App may signal cellphone dependency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading ... Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly ... CBD form that can be easily incorporated into liquid products, while reducing costs to ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)...  Caris Life Sciences ® , a leading innovator ... precision medicine, today announced that St. Jude Medical Center,s ... (POA) as its 17 th member. Through participation ... Cancer Institute will help develop standards of care and ... making cancer treatment more precise and effective. ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology: